Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now

SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets